Catalog No.
KDB94401
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant human TNFa antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled Adalimumab and then pipetted into the wells. Adalimumab in the sample competitively binds to the pre-coated protein with biotin-labeled Adalimumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Adalimumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Adalimumab concentration in serum, plasma and cell culture supernatant.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31-5 μg/mL
Sensitivity
0.156 μg/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 20% prior to the expiration date under appropriate storage condition.
Alternative Names
ABP 501, D2E7, Adalimumab, CAS: 331731-18-1
Background
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for Tumor Necrosis Factor-Alpha (TNF-a) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Adalimumab specifically binds to TNF alpha and blocks its interaction with p55 and p75 cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.
For research use only. Not for human or drug use.
